Clinical trial
A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen
NCT00640627 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 31, 2003
- Completion date
- September 30, 2004
- Enrollment
- 380 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.